Treating hepatitis C virus infection
Methods and compositions are provided to inhibit release of HCV from an HCV-infected cell by contacting the cell with a VLDL assembly inhibitor, and detecting a resultant inhibition of HCV release from the cell. The methods can be used to decrease serum viremia of an HCV-infected person.
1. A method of decreasing serum viremia of an hepatitis C virus (HCV)-infected person, the method comprising the step of administering to the person an effective amount of lomitapide (BMS-201038; N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4′-(trifluoromethyl)[1,1′-biphenyl]2-yl]carbonyl]amino]-1-piperidinyl]butyl]9H-fluoren-9-carboxamde), wherein a resultant decrease in the serum viremia is effected by a submicromolar concentration of the lomitapide.
2. The method of claim 1 wherein the administering step comprises delivering to the person 1 mg/kg body weight per day or less of the lomitapide for a duration sufficient to decrease the viremia.
3. The method of claim 1 wherein the administering step comprises delivering to the person 0.1 mg/kg body weight per day or less of the lomitapide for a duration sufficient to decrease the viremia.
4. The method of claim 1 further comprising the step of detecting a resultant decrease in serum viremia in the person.
5. The method of claim 1 wherein the administering step comprises delivering to the person 0.1 mg/kg body weight per day or less of the lomitapide for a duration sufficient to decrease the viremia, further comprising the step of detecting a resultant decrease in serum viremia in the person.
6. The method of claim 1 wherein the administering step further comprises administering to the person an antiviral agent selected from interferon and ribavirin.
7. The method of claim 1 , wherein the person is determined to be nonresponsive to interferon monotherapy.
8. The method of claim 1 , wherein the person is positive for HCV after at least 3 months of interferon therapy.
9. The method of claim 1 wherein the administering comprises delivering to the person 0.1 mg/kg body weight per day or less of the lomitapide for a duration sufficient to decrease the viremia, further comprising the step of detecting a resultant decrease in serum viremia in the person, the administering step further comprises administering to the person an antiviral agent selected from interferon and ribavirin, and the person is positive for HCV after at least 3 months of interferon therapy.
10. A method of treating a hepatitis C virus (HCV) infection in a person determined to be HCV-infected, comprising the step of administering to the person lomitapide (BMS-201038; N-(2,2,2-trifluoroethyl)-9-[4-[4-[[[4′-(trifluoromethyl)[1,1′-biphenyl]2-yl]carbonyl]amino]-1-piperidinyl]butyl]9H-fluoren-9-carboxamde), wherein a resultant decrease in the serum viremia is effected by a submicromolar concentration of the lomitapide.
11. The method of claim 10 , wherein the patient is determined to be nonresponsive to interferon monotherapy.
12. The method of claim 10 , wherein the patient is positive for HCV after at least 3 months of interferon therapy.
13. The method of claim 10 wherein the administering step comprises delivering to the person 1 mg/kg body weight per day or less of the lomitapide for a duration sufficient to decrease the viremia.
14. The method of claim 10 wherein the administering step comprises delivering to the person 0.1 mg/kg body weight per day or less of the lomitapide for a duration sufficient to decrease the viremia.
15. The method of claim 10 further comprising the step of detecting a resultant decrease in serum viremia in the person.
16. The method of claim 10 wherein the administering step comprises delivering to the person 0.1 mg/kg body weight per day or less of the lomitapide for a duration sufficient to decrease the viremia, further comprising the step of detecting a resultant decrease in serum viremia in the person.
17. The method of claim 10 wherein the administering step further comprises administering to the person an antiviral agent selected from interferon and ribavirin.
18. The method of claim 10 wherein the administering comprises delivering to the person 0.1 mg/kg body weight per day or less of the lomitapide for a duration sufficient to decrease the viremia, further comprising the step of detecting a resultant decrease in serum viremia in the person, the administering step further comprises administering to the person an antiviral agent selected from interferon and ribavirin, and the person is positive for HCV after at least 3 months of interferon therapy.
19. The method claim 1 wherein the submicromolar concentration is less than 100 nM.
20. The method claim 10 wherein the submicromolar concentration is less than 100 nM.